The implant helps native meniscal tissue regenerate instead of needing to cut or replace it, according to a news release. An animal study also found that RejuvaKnee could withstand full weight bearing, and the knee returned to full range of motion after three months of implantation.
RejuvaKnee is the 60th FDA-cleared product from Regenity Biosciences.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
